Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (TCTR20260723007) titled 'Prospective study of aspirin resistance between 81 mg once daily vs 81 mg twice daily in splenectomized thalassemic patients' on July 23.
Study Type: Interventional
Study Design:
N/A
Primary Sponsor: -
Condition:
Dose escalation of aspirin in certain splenectomized thalassemic patients could potentially overcome aspirin resistance, and subsequently lower the incidence of future thromboembolic events.
aspirin, aspirin resistance, thromboembolic event, splenectomized thalassemic patients
aspirin, aspirin resistance, thromboembolic event, splenectomized thalassemic patients
Intervention:
This study enrolled...